UBS Starts Crinetics (CRNX) at Buy

July 2, 2026 4:17 AM

UBS analyst Ashwani Verma initiates coverage on Crinetics (NASDAQ: CRNX) with a Buy rating and a price target of $55.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found